Innovative treatments: ethical requirements for evaluation
Identifieur interne : 001E29 ( Main/Exploration ); précédent : 001E28; suivant : 001E30Innovative treatments: ethical requirements for evaluation
Auteurs : G. R Gillett [Nouvelle-Zélande]Source :
- Journal of Clinical Neuroscience [ 0967-5868 ] ; 1997.
Abstract
An innovative surgical treatment may arise as a deliberate strategy to solve a clinical problem or as a serendipitous discovery in the course of clinical care. In either case there is a need to evaluate the procedure and there are ethical requirements on such evaluation concerning the reasons for its introduction, patient consent, patient safety and clinical efficacy. Some of these ethical considerations may tell against a randomized controlled trial but the need for monitoring and evaluation along with genuine informed consent remain as absolute requirements. Two cases are introduced and discussed, one of which concerns potentially dangerous surgery and the other a new technology. In each case the ethical requirements are examined and discussed and the possible substitutes for prospective randomized controlled studies in clinical surgery are explored. It is concluded that there are defensible and scientific ways to introduce surgical innovation even where the ‘gold standard’ of a prospective randomized controlled trial cannot be met.
Url:
DOI: 10.1016/S0967-5868(98)90265-X
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Innovative treatments: ethical requirements for evaluation</title><author><name sortKey="Gillett, G R" sort="Gillett, G R" uniqKey="Gillett G" first="G. R" last="Gillett">G. R Gillett</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4C60843261B22D3263F0FD1AE1382069880199C7</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0967-5868(98)90265-X</idno><idno type="url">https://api.istex.fr/document/4C60843261B22D3263F0FD1AE1382069880199C7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003161</idno><idno type="wicri:Area/Main/Curation">002D62</idno><idno type="wicri:Area/Main/Exploration">001E29</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Innovative treatments: ethical requirements for evaluation</title><author><name sortKey="Gillett, G R" sort="Gillett, G R" uniqKey="Gillett G" first="G. R" last="Gillett">G. R Gillett</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Department of Neurosurgery, Dunedin Public Hospital, Dunedin</wicri:regionArea><wicri:noRegion>Dunedin</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Clinical Neuroscience</title><title level="j" type="abbrev">YJOCN</title><idno type="ISSN">0967-5868</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">5</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="378">378</biblScope><biblScope unit="page" to="381">381</biblScope></imprint><idno type="ISSN">0967-5868</idno></series><idno type="istex">4C60843261B22D3263F0FD1AE1382069880199C7</idno><idno type="DOI">10.1016/S0967-5868(98)90265-X</idno><idno type="PII">S0967-5868(98)90265-X</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0967-5868</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An innovative surgical treatment may arise as a deliberate strategy to solve a clinical problem or as a serendipitous discovery in the course of clinical care. In either case there is a need to evaluate the procedure and there are ethical requirements on such evaluation concerning the reasons for its introduction, patient consent, patient safety and clinical efficacy. Some of these ethical considerations may tell against a randomized controlled trial but the need for monitoring and evaluation along with genuine informed consent remain as absolute requirements. Two cases are introduced and discussed, one of which concerns potentially dangerous surgery and the other a new technology. In each case the ethical requirements are examined and discussed and the possible substitutes for prospective randomized controlled studies in clinical surgery are explored. It is concluded that there are defensible and scientific ways to introduce surgical innovation even where the ‘gold standard’ of a prospective randomized controlled trial cannot be met.</div></front></TEI><affiliations><list><country><li>Nouvelle-Zélande</li></country></list><tree><country name="Nouvelle-Zélande"><noRegion><name sortKey="Gillett, G R" sort="Gillett, G R" uniqKey="Gillett G" first="G. R" last="Gillett">G. R Gillett</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4C60843261B22D3263F0FD1AE1382069880199C7
|texte= Innovative treatments: ethical requirements for evaluation
}}
| This area was generated with Dilib version V0.6.23. |  |